Different NIPTs for different patient needs
No other genetic testing laboratory currently offers as much expertise, experience, and choice in NIPT—noninvasive prenatal testing, also called NIPS or cfDNA (cell-free DNA) screening.
With the 2016 acquisition of Sequenom, creator of the first commercially available NIPT, Integrated Genetics now offers three NIPTs—with more than 1 million tests run in total.
Each NIPT offers different capabilities and/or panels to suit the specific needs of your patients and your practice.
|MaterniT® GENOME||MaterniT® 21 PLUS||informaSeq®|
|Detects trisomy 21 (Down syndrome)|
|Detects trisomy 18 (Edwards syndrome)|
|Detects trisomy 13 (Patau syndrome)|
|Detects sex chromosome abnormalities*|
|Reports fetal fraction|
|Reports fetal sex*|
|Detects additional trisomies 22, 16*|
|Detects select microdeletions, such as 22q11.2 (DiGeorge syndrome)**|
|Performed as early as 9 weeks|
|~5 calendar day turnaround time|
|Genome-wide analysis of all chromosomes|
|Reports on any trisomy or monosomy|
|Detects subchromosomal abnormalities ≥ 7 Mb|
MaterniT 21 PLUS, MaterniT GENOME, and informaSeq are laboratory-developed test developed and performed exclusively by Integrated Genetics.
* Optional reporting † informaSeq is validated for singleton and twin pregnancies ** Optional reporting for MaterniT 21 PLUS
- Ehrich M, Tynan J, Mazloom A, Almasri E, McCullough R, Boomer T, et al. Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases. Genet Med. 2017 Jun 15. 1-6.